Point-of-Care Testing and Pandemic Preparedness Drive Robust Market Growth
According to a new report by MarketsandMarkets™, the global lateral flow assays (LFA) market was valued at USD 7.93 billion in 2024, grew to USD 8.51 billion in 2025, and is projected to expand at a CAGR of 8.0% from 2025 to 2030, reaching USD 12.52 billion by 2030.
The market’s growth is being driven by the increasing need for rapid, easy-to-use diagnostic solutions, expanding point-of-care testing, and heightened focus on infectious disease management and pandemic preparedness.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=167205133
Lateral Flow Assays: Transforming Rapid Diagnostics
Lateral flow assays are simple, rapid diagnostic tests widely used for infectious disease detection, pregnancy testing, and biomarker analysis. LFAs are increasingly adopted in hospitals, clinics, and home-based testing due to their ease of use, affordability, and rapid results.
The growing prevalence of COVID-19, influenza, HIV, and other infectious diseases has reinforced the importance of point-of-care diagnostics, positioning LFAs as a key technology for quick and reliable screening.
Key Market Drivers
-
Rising Demand for Point-of-Care Testing: The shift toward decentralized diagnostics is driving adoption in clinics, pharmacies, and home settings.
-
Technological Advancements: Innovations like multiplex LFAs, digital readers, and smartphone integration enhance sensitivity and usability.
-
Public Health Initiatives: Government programs promoting early disease detection and rapid testing infrastructure support market growth.
-
Global Pandemic Preparedness: The COVID-19 pandemic has accelerated investment in rapid diagnostic tools and supply chain expansion.
Market Segmentation Highlights
-
By Product Type: Strips, cassettes, and cards dominate the market, with increasing interest in digital and multiplex formats.
-
By End User: Hospitals, diagnostic laboratories, and home-use settings are major contributors to growth.
-
By Application: Infectious diseases, oncology, and reproductive health remain key application areas.
Regional Insights
-
North America leads the market due to advanced healthcare infrastructure, strong R&D, and high awareness of point-of-care diagnostics.
-
Europe shows steady growth with expanding clinical applications and government support for public health screening programs.
-
Asia-Pacific is emerging as a high-growth market, driven by increasing healthcare access, rising infectious disease incidence, and expanding diagnostic networks.
Future Outlook
The lateral flow assays market is set for continued expansion as digitalization, AI integration, and multiplex testing transform rapid diagnostics. By 2030, LFAs will play a critical role in early detection, outbreak management, and personalized healthcare, ensuring faster, more accessible diagnostic solutions globally.